A Clinical Study on Pulsed Low Dose Rate Radiation Therapy for Recurrent Cancers

X Tong*, FS Luo, GR Yang, DP Wang, X Song, Y Chen, S Wu, N Zhang, QQ Xu, T Zhang, and J Li
3rd Affiliated Hospital of Qiqihar Medical University, Qiqihar, China

ABSTRACT
A consensus standard of care has not been established for treating recurrent cancer patients who have previously undergone radiation therapy (RT). Several in vitro and in vivo studies have shown that pulsed low-dose-rate RT (PLDR) has the potential to reduce normal tissue toxicities while still providing significant tumor control for recurrent cancers. This work investigated PLDR re-irradiation for patients with recurrent cancers in head and neck (H&N), lung and pelvis. Thirteen patients with recurrent cancer were treated with the PLDR technique between 2012 and 2014. The re-irradiation sites included neck nodes, lung, chest wall, thyroid, pelvic nodes, pelvic nodes, uterus, cervix and vagina, supraclavicular nodes, and spine. The previous dose was ≥ 50Gy for all patients, while the re-irradiation dose was 16-60Gy. The interval between prior RT treatment and re-irradiation was 13 – 336 months, and the follow-up time was up to 27 months. The PLDR treatments were effective (CR: 3 patients, PR: 10 patients). The acute and late toxicities were all acceptable (generally grade 2 or under). Our preliminary clinical results demonstrated the effectiveness of the PLDR technique for the palliative treatment of recurrent H&N, lung, rectal and gynecologic cancers. Further clinical trials are warranted to quantify the efficacy of PLDR for recurrent cancers and other radiation resistant cancers and/or large treatment volumes involving critical structures.

Keywords: Pulsed low dose-rate RT (PLDR), re-irradiation, recurrent cancer, dose rate effect, tumor control, normal tissue toxicities

INTRODUCTION
Many technological developments have been made for radiation therapy over the last several decades including computer controlled linear accelerators, multi-leaf collimators (MLC), treatment planning systems and optimization techniques, and various imaging modalities and treatment targeting/guidance techniques (Mayles et al. 2007). Radiobiology plays an important role in the design of new radiotherapy trials to explore novel treatment strategies such as dose escalation and hypo/hyper-fractionation that employ advanced delivery techniques such as intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and particle therapy (Kavanagh and Timmerman...
Pulsed low-dose-rate radiotherapy (PLDR) is a novel treatment technique designed for re-irradiation of recurrent cancers (Tomé and Howard 2007, Richards et al. 2009, Adkison et al. 2011, Ma et al. 2011). It takes advantages of the hyper-radiosensitivity (HRS) of tumor cells below a certain low dose level (i.e., the transition dose), which is generally greater than those of normal tissues, and the increased normal tissue repair at low dose rates (Joiner et al. 2001, Steel 2002, Short et al. 2001, Harney et al. 2004, Wykes et al. 2006, Marples and Collis 2008). This is achieved by dividing a daily radiotherapy treatment into a number of subfractions (pulses) with each subfractional dose less than the tumor transition dose but greater than the normal tissue transition dose so that the radiation damage repair is triggered in normal tissues but not in tumor cells, resulting in an improvement in the therapeutic ratio. PLDR treatment can be delivered on conventional clinical accelerators with simple 2D/3D conformal beam arrangements or on advanced beam delivery systems employing IMRT/VMAT and treatment optimization algorithms (Rong et al. 2011, Ma et al. 2012, Lin et al. 2013, Tyagi et al. 2013, Kang et al. 2014, Li et al. 2014, Murphy et al. 2017, Geurts 2017).

Extensive in vivo experiments have been carried out to test the hypothesis of PLDR in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP). Longer tumor growth delay was observed in many human tumor xenografts treated with PLDR than with conventional RT (Park et al. 2011, Dilworth et al. 2013, Zhang et al. 2015, Wang et al. 2020). PLDR also improved normal tissue toxicities in treated animals with fewer normal neuronal cell deaths (Park et al. 2011), less brain damage (Lee et al. 2013), better preserved vasculature (Dilworth et al. 2013, Meyer et al. 2016), and less damage to the gastrointestinal system (e.g., the stomach) and the immune and hematopoietic systems (e.g., spleen and bone marrow) (Zhang et al. 2015). Several phase I clinical trials have been conducted to exploit the therapeutic potential of PLDR for cancer treatments (Richards et al. 2009, Ma and Meyer 2011, Adkison et al. 2011, Mohindra et al. 2013, Magnuson et al. 2014, Meyer 2017, Burr et al. 2020, Bovi et al. 2020, Meyer 2020). Preliminary results from these clinical trials and other pioneering studies have shown favorable outcomes in TCP and NTCP for various cancers especially for recurrent cancers, bulky/radioresistant tumors and refractory patients (Richards et al. 2009, Adkison et al. 2011, Mohindra et al. 2013, Magnuson et al. 2014, Lee et al. 2018, Yan et al. 2018, Rogacki et al. 2018, Witt et al. 2019, Burr et al. 2020, Chen 2020).

A consensus standard of care has not been established for treating recurrent cancer patients, who have previously undergone radiation. In this work, we explored the clinical potential of PLDR for recurrent cancers in head and neck (H & N), lung and pelvis. Thirteen recurrent patients were treated using the PLDR delivery technique with 3D conformal radiotherapy (3DCRT) and followed up for 27 months. Here we present the outcome of PLDR treatment including tumor control and acute/late normal tissue toxicities. Preliminary results of this study were presented at the American Society for Radiation Oncology (ASTRO) 2015 annual meeting (Tong et al. 2015).

**MATERIALS AND METHODS**

**The Patient**

Thirteen patients with recurrent cancer were recruited for this study. Among them, 10 were male and 3 were female, aged between 49 and 74. The patients were treated with the PLDR technique between 2012 and 2014 using the 3DCRT treatment technique. The re-irradiation sites included neck nodes (3), lung (3), chest wall (2), thyroid (1), pelvic nodes (1), pelvic nodes, uterus, cervix and vagina (1), supraclavicular nodes (1), and spine (1). The interval between previous RT and re-irradiation was 13 – 336 months, and the follow-up time was up to 27 months.

**The PLDR technique**

PLDR is a novel treatment technique, which can be delivered using conventional clinical machines using both simple 2D/3D beam arrangements or advanced IMRT/VMAT treatment techniques. The hypothesis of PLDR is to take advantage of both the low-dose HRS for tumors and the increased DNA repair at low dose rates for normal tissues by dividing the total daily dose into subfractions (pulses) of small doses and delivering them within a limited time frame to achieve an effective low dose rate. In this work, we have followed the proposal of Tomé and Howard (2007) by dividing a daily dose of 2 Gy into 10 pulses of 0.2 Gy with a 3-minute time interval (from the start of one pulse to the start of the next), resulting in an effective dose rate of 0.067 Gy/minute.

**PLDR planning and treatment**

The patients were treated on a Siemens Primus linear accelerator (Siemens Medical Systems, Concord, CA) and the 3DCRT plans were created using the Topslane 3D TPS (Topslane Inc, Suzhou, China). The clinical target volume...
(CTV) for these patients ranged between 161 and 703cc. The previous dose was >50 Gy for all patients, while the re-irradiation dose ranged between 16 and 60 Gy. Optimal beam angles were used to avoid organs at risk (OAR) in order to meet the OAR dose constraints as much as possible, which were the same as those used in the initial treatment. The dose was prescribed to the centroid of the planning target volume (PTV). The maximum dose in the PTV was less than 110% of the prescription dose and the minimum dose was better than 98% of the prescription dose. The maximum dose per pulse at any point of the PTV was less than 0.3 Gy, which is less than the transition dose for most tumors (Hall and Brenner 1991, Joiner et al. 2001, Wykes et al. 2006, Marples and Collis 2008). The daily 2 Gy dose was divided into 10 sub-fractions (pulses) of 0.2 Gy and delivered with a time interval of 3 minutes (using a stopwatch) to obtain an effective dose rate of 0.067 Gy/minute.

RESULTS
We have treated 13 recurrent patients in this study. Primary cancer sites included head and neck, lung and pelvis (rectum and gynecologic cancers, GYN). Figure 1 shows the number of patients for different recurrent cancers. Table 1 shows the primary cancer sites, the previous doses received and the re-irradiation doses prescribed to the PLDR treatment volume in this study. The maximum prescription dose received in previous RT treatment was 66 Gy and the minimum prescription dose was 40 Gy, which was for a previous stereotactic body radiotherapy (SBRT) patient. The maximum prescription dose for PLDR the re-irradiation treatment was 60 Gy and the minimum prescription dose was 16 Gy for a recurrent H&N patient.

Table 1: The previous dose received and the re-irradiation dose prescribed for the PLDR treatment.

<table>
<thead>
<tr>
<th>Tumor Site</th>
<th>Previous dose (Gy)</th>
<th>Re-irradiation dose (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;N</td>
<td>66 × 1</td>
<td>60 × 1</td>
</tr>
<tr>
<td></td>
<td>60 × 3</td>
<td>50 × 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16 × 1</td>
</tr>
</tbody>
</table>

Figure 1: Number of patients per treatment site
The PLDR treatments were effective for all patients with good local control and acceptable normal tissue toxicities. Figure 2 shows MR images of a head and neck patient before and 10 weeks post PLDR treatment. Two patients died three months after the PLDR re-irradiation, one due to a massive cerebral infarction and the other due to acute cardiac failure. All others survived more than 8 months by February 2015. Five patients showed good conditions at the last follow-up. Among them two recurrent lung cancer patients had survived 23 months and one nasopharyngeal cancer patient had survived 27 months.

Table 2: The clinical outcome for the 13 recurrent patients treated with PLDR.

<table>
<thead>
<tr>
<th>Tumor site</th>
<th>Local control</th>
<th>Acute toxicity (grade)</th>
<th>Late toxicity (grade)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;N</td>
<td>CR × 1</td>
<td>Xerostomia (1) × 2</td>
<td>Skin fibrosis (3) × 2</td>
</tr>
<tr>
<td></td>
<td>PR × 3</td>
<td>Mucositis (2) × 2</td>
<td>Skin fibrosis (2) × 1</td>
</tr>
<tr>
<td>Lung</td>
<td>CR × 1</td>
<td>No</td>
<td>Hyperpigmentation (2) × 3</td>
</tr>
<tr>
<td></td>
<td>PR × 5</td>
<td></td>
<td>Xerostomia (1) × 3</td>
</tr>
<tr>
<td>GYN</td>
<td>PR × 2</td>
<td>GI toxicity (1) × 2</td>
<td>No</td>
</tr>
<tr>
<td>Rectum</td>
<td>CR × 1</td>
<td>GI toxicity (1) × 1</td>
<td>No</td>
</tr>
</tbody>
</table>

Table 2 summarizes our clinical observations including local tumor control, acute and late normal tissue toxicities for the 13 patients treated with PLDR. Complete response (CR) was seen in 3 patients: 1 in H&N, 1 in lung and 1 in rectum. Partial response (PR) was seen in 10 patients: 3 in H&N, 5 in lung and 2 in GYN. The acute toxicities included xerostomia, mucositis, and GI toxicities, which were all grade 2 or under. The late toxicities included hyperpigmentation, xerostomia and radiation pneumonitis, which were all grade 2 or under, except for a H&N patient, who had grade 3 skin fibrosis.
DISCUSSION

PLDR has been explored by other investigators for treating recurrent H&N cancer. A case report was presented by Li et al. (2012) on PLDR re-treatment of recurrent poorly differentiated squamous cell carcinoma of the nasopharynx metastatic to a cervical lymph node. The initial dose was 70 Gy to the gross tumor volume and a metastatic lymph node, and ≥ 50 Gy to the bilateral cervical lymphatics. An additional 60 Gy was delivered to recurrent metastatic lymph nodes in the neck 5 years later. A second recurrence was discovered a year later and treated with PLDR of 70 Gy. In total, the patient received up to 190 Gy to the recurrence region. The recurrent lesion had a complete response to PLDR with no apparent radiation-induced normal tissue complications (only Grade 1 acute skin toxicity). In comparison, we treated 4 H&N recurrent patients using PLDR in this work. The total dose received by the recurrent tumor sites varied between 82 Gy and 126 Gy. We also achieved good local control (1 CR and 3 PR) with acceptable acute and late toxicities.

The Fox Chase group was the first to investigate advanced delivery techniques systematically for PLDR treatment of recurrent cancers to further reduce normal tissue toxicities (Ma et al. 2012, Lin et al. 2013, Li et al. 2014, Kang et al. 2014). These delivery techniques were used in their phase I dose escalation trial to investigate PLDR irradiation for palliation of recurrent tumors (Ma and Meyer 2011). Lee et al. (2019) evaluated 39 patients treated with PLDR re-irradiation from 2009 to 2016 from their institution. The median follow-up time was 8.8 months and the median interval from the first radiation course and re-irradiation was 26.2 months. The median dose for the first and second course of radiation was 50.4 Gy and 50 Gy, respectively. The local progression rate was 16.5% at 6 months and 23.8% at 12 months. Of the 41 disease sites for the 39 patients, 25 (61%) were in the thoracic region including non-small cell lung and esophagus. For these thoracic patients 12 developed grade 1, 4 developed grade 2 and 4 developed grade 3 acute toxicities, and only 1 patient developed grade 1 late toxicity. In our study, 6 patients were treated with 3DCRT for recurrent primary lung or metastases. The prescription dose from the previous treatment ranged from 40 to 60 Gy and the prescription dose for the PLDR retreatment ranged from 30 to 60 Gy (maximum dose in the overlapping region 120 Gy). Good local tumor control was achieved with 1 CR and 5 PR. No acute toxicities were observed and only one patient developed grade 2 radiation pneumonitis.

Paly et al. (2020) reported PLDR re-irradiation of 38 pelvic patients between 2010 and 2019 using 3DCRT, IMRT and VMAT delivery techniques. Median follow-up was 10.4 months. The tumor re-irradiation target site included prostate, rectal, bladder, gynecologic cancers, etc. The prior overlapping dose was 35 - 80 Gy EQD2 for 31 EBRT patients with known initial RT history. Four patients received initial LDR prostate brachytherapy (115 to 145 Gy). Twenty-three patients were treated with definitive intent to 50 - 76 Gy. The one-year Kaplan-Meier local progression-free proportion based on clinical, biochemical, or radiographic response was 59% and 6 of 23 patients had no evidence of disease at their last follow-up. For 12 patients with available follow-up imaging, the best local tumor response was CR in 8%, PR in 42%, stable disease (SD) in 25%, and progressive disease...
(PD) in 25%. For 15 patients treated palliatively (28 to 60 Gy), the one-year Kaplan-Meier local progression-free proportion based on clinical or radiographic response was 61% and the best local tumor response was PR in 33%, SD in 53%, and PD in 13%. Acute skin/soft tissue grade 1 and 2 toxicity was 5.3% and 5.3%, respectively. Late skin/soft tissue grade 2 toxicity was 2.6%. Acute GU grade 1 and 2 toxicity was 7.9% and 21.1%, respectively. Late GU grade 1, 2, and 3 toxicity was 13.2%, 10.5%, and 5.3%, respectively. Acute GI grade 1 and 2 toxicity was 7.9% and 2.6%, respectively. Late GI grade 1, 2, and 3 toxicity was 13.2%, 5.3%, and 2.6%, respectively. In our study, 2 GYN and 1 rectal cancer patients were treated with PLDR with good outcome, the local tumor response was CR for the rectal patient and PR for the 2 GYN patients. Patients only had acute GI grade 1 toxicity without any late toxicities observed.

In conclusion, we have successfully treated 13 recurrent patients with PLDR. Our results showed favorable clinical outcome in tumor control and acute/late normal tissue toxicities as reported by other investigators. PLDR and infrequent concurrent chemotherapy provided tumor control for the majority of patients for whom few if any, other options for local treatment existed. PLDR represents a viable option in cancer management, especially for patients in whom re-irradiation is otherwise high risk.

ACKNOWLEDGEMENT

We would like to thank Dr. Charlie Ma and other colleagues at Fox Chase Cancer Center for useful discussions and clinical guidance on PLDR treatment and planning.

REFERENCES


